Shanghai Runda Medical Technology Co., Ltd. (603108.SS) has a MoatMap StockRank of 21/100 based on Quality (35/100), Value (37/100), and Momentum (34/100) factor scores. The current signal is SELL. Shanghai Runda Medical is an in-vitro diagnostics distributor and IT provider. It suffers from high working capital constraints, long receivable cycles from Chinese hospitals, and low organic cash generation.
Shanghai Runda Medical Technology Co., Ltd. provides comprehensive in-vitro diagnostic (IVD) products and integrated laboratory services to hospitals and medical institutions. The company's competitive moat lies in its integrated supply service model, which bundles product distribution with technical support and laboratory management. It is a leading player in China's IVD distribution and service market, benefiting from long-term hospital partnerships.
| Price | $1.53 |
| Market Cap | $1.1B |
| P/E (Forward) | 16.00 |
| Price/Book | 1.89 |
| Return on Equity | -9.7% |
| Return on Invested Capital | -3.2% |
| Debt/Equity | 142.10 |
| Gross Margin | 21.9% |
| Operating Margin | 1.1% |
| Revenue Growth | -9.1% |
| Dividend Yield | 0.3% |
| Free Cash Flow | $9M |
Shanghai Runda Medical Technology Co., Ltd. operates in the Diagnostics & Research industry, part of the Healthcare sector (China).